Stephen Ford
Endocrinology, Diabetes & Metabolism · New Orleans, LANPI 1649739715
Payments from drug & device makers
Across 46 payments — averaging $25.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$182
- Chiesi USA, Inc.$130
- TG Therapeutics, Inc.$93
- Novo Nordisk$85
- Dexcom, Inc.$72
- Genentech USA, Inc.$67
- plus $548 from 18 others
What the payments were for
- Food & beverage$1,178100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,178 in reported general payments places this provider in the 30th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $28,275 |
| JardianceEmpagliflozin | 20 | $19,281 |
| TrulicityDulaglutide | 20 | $18,032 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,440 |
| Metformin Hcl ErMetformin Hcl | 24 | $730 |
| Desmopressin Acetate | 14 | $596 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $406 |
| Hydrocortisone | 19 | $334 |
| Levothyroxine Sodium | 42 | $216 |
| Rosuvastatin Calcium | 27 | $212 |
| Atorvastatin Calcium | 28 | $188 |
| Amlodipine Besylate | 13 | $50 |
| Alendronate Sodium | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $85 | $28,27517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in New Orleans
- Vivian FonsecaNew Orleans$700K
- Dragana LovreNew Orleans$231K
- Lawrence BlondeNew Orleans$190K
- Bryan GrissettNew Orleans$8K
- Melina Roman-GerardinoNew Orleans$7K
- Mariam MenhemNew Orleans$5K
- Nyrene HaqueNew Orleans$5K
- Sarah SternliebNew Orleans$2K
- Suneeta GanjiNew Orleans$2K
- Tuan Huy TranMetairie$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.